A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Combination with Melphalan and Dexamethasone in Subjects with Newly-Diagnosed Light-Chain (AL)-Amyloidosis.
Philippe Moreau(Centre National de la Recherche Scientifique), Jean‐Paul Fermand(Sorbonne Université), Valérie Coiteux(Lille’s Cardiology Hospital), Olivier Hermine(Centre National de la Recherche Scientifique), Lotfi Benboubker, Bruno Royer(Centre Hospitalier Universitaire Amiens-Picardie), Catherine Traullé(Université de Lyon), Frank Bridoux(Université de Poitiers), B. Grosbois(Centre Hospitalier Universitaire de Rennes), Véronique Leblond(Sorbonne Université), May Alakl(Goethe University Frankfurt), Jean‐Luc Harousseau(Institut de Cancérologie de l'Ouest), Arnaud Jaccard(Centre Hospitalier Universitaire de Limoges)
Cited by 3
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2016|1.1k